Cervical Cancer Screening Interval (NHSCSP / HPV Primary)
HPV Test Result
Cytology (if HPV positive)
Detaljerad guide kommer snart
Vi arbetar på en omfattande utbildningsguide för Cervical Cancer Screening Interval. Kom tillbaka snart för steg-för-steg-förklaringar, formler, verkliga exempel och experttips.
Cervical cancer is caused by persistent infection with high-risk strains of human papillomavirus (HPV), particularly HPV types 16 and 18, which together account for approximately 70% of all cervical cancers. HPV is the most common sexually transmitted infection globally, with transient infection occurring in approximately 80% of sexually active women at some point, but only a small proportion develop persistent infection leading to cervical intraepithelial neoplasia (CIN) and invasive cancer. Cervical cancer is the fourth most common cancer in women worldwide, with approximately 604,000 new cases and 342,000 deaths globally per year (2020 data). In high-income countries, widespread HPV vaccination and organised cervical screening programmes have dramatically reduced incidence, while in low-income countries without comprehensive screening, it remains a leading cause of cancer death in women. In the UK (2019 NHS screening programme) and US (2021 USPSTF guidelines), primary HPV testing has replaced cytology (Pap smear) as the first-line cervical screening test, given its higher sensitivity for CIN2+ detection. UK screening: women aged 25–49 screened every 3 years; 50–64 every 5 years. US: HPV co-testing or primary HPV testing every 5 years from age 25–65. Women testing HPV16/18 positive are referred directly to colposcopy regardless of cytology. Women positive for other high-risk HPV types with abnormal cytology are also referred for colposcopy. CIN is graded 1 (low-grade, usually self-limiting), 2 (intermediate), or 3 (high-grade precancer requiring treatment). LEEP/LLETZ (loop excision) and cone biopsy are the main treatment modalities for CIN 2–3.
Cervical screening interval: 25-49yr = every 3 years (UK); 50-64yr = every 5 years (UK); Primary HPV test positive for HPV16/18 = immediate colposcopy referral; positive other hrHPV + abnormal cytology = colposcopy referral
- 1At the recommended screening interval, collect a cervical sample using a brush device (now predominantly self-sampling in some countries); laboratory performs primary HPV DNA testing.
- 2If HPV negative: woman returns to routine 3- or 5-year recall; further cytology is not required in primary HPV screening programmes.
- 3If HPV positive: reflex cytology is performed on the same sample to stratify risk.
- 4If HPV 16/18 positive (regardless of cytology) OR any hrHPV positive with abnormal cytology (borderline, low-grade or high-grade dyskaryosis): refer for colposcopy.
- 5At colposcopy: apply acetic acid (3% or 5%) to the cervix; acetowhite lesions (turning white on acid application) indicate CIN; visualise the transformation zone; perform targeted punch biopsies of suspicious areas.
- 6Classify CIN grade on histology: CIN1 (mild dysplasia) — monitor; CIN2 (moderate) — treat or monitor depending on age and immune status; CIN3 (severe/CIS) — treat.
- 7Treatment: large loop excision of the transformation zone (LLETZ/LEEP) is first-line for CIN 2–3; cold coagulation is an alternative; cone biopsy is used for inadequate colposcopy or glandular lesions; post-treatment follow-up involves HPV testing at 6 months.
HPV-negative result has >99% NPV for significant CIN for at least 3-5 years
A negative primary HPV test provides strong reassurance against CIN for the next screening interval. No further action required beyond returning to routine recall.
Risk of CIN3+ in HPV16-positive women is approximately 25-30% over 5 years
HPV 16 and 18 carry the highest cancer risk of all HPV types. UK and US guidelines mandate direct colposcopy referral for all HPV16/18 positive women, irrespective of cytology result.
Approximately 50% of CIN 2 regresses spontaneously, particularly in women under 30; LLETZ has a 1-2% risk per procedure of preterm birth in future pregnancies
BSCCP guidelines support active surveillance (colposcopy every 6 months) for CIN 2 in women under 30 as an acceptable alternative to immediate treatment, due to high spontaneous regression rates and LLETZ-associated preterm birth risk.
Recurrence after LLETZ for CIN 3: approximately 5-10%; post-treatment surveillance for 10 years in UK programme
CIN 3 (high-grade CIN or carcinoma in situ) requires treatment to prevent progression to invasive cancer, which occurs in an estimated 30-50% of untreated CIN 3 over 20-30 years. LLETZ achieves clear excision in approximately 85-90% of cases at first attempt.
Primary cervical screening programmes to identify women with high-risk HPV infection requiring further investigation, enabling practitioners to make well-informed quantitative decisions based on validated computational methods and industry-standard approaches, which requires precise quantitative analysis to support evidence-based decisions, strategic resource allocation, and performance optimization across diverse organizational contexts and professional disciplines
Colposcopy clinics to diagnose CIN grade and plan treatment, helping analysts produce accurate results that support strategic planning, resource allocation, and performance benchmarking across organizations, where accurate numerical computation is essential for producing reliable outputs that inform planning, evaluation, and continuous improvement processes in both corporate and individual settings
Post-LLETZ surveillance to confirm treatment success and detect recurrence, allowing professionals to quantify outcomes systematically and compare scenarios using reliable mathematical frameworks and established formulas, demanding systematic calculation approaches that translate raw input data into actionable insights for stakeholders who depend on quantitative rigor in their daily professional activities
HPV vaccination programmes targeting adolescents before first sexual activity, supporting data-driven evaluation processes where numerical precision is essential for compliance, reporting, and optimization objectives, necessitating robust computational methods that deliver consistent and verifiable results suitable for reporting, auditing, and long-term trend analysis in professional environments
Public health monitoring of cervical cancer incidence trends to evaluate screening and vaccination programme effectiveness, which requires precise quantitative analysis to support evidence-based decisions, strategic resource allocation, and performance optimization across diverse organizational contexts and professional disciplines
Immunosuppressed women
Women with HIV, on immunosuppressive therapy (organ transplant, biological drugs), or with other causes of immunosuppression have impaired HPV clearance and faster CIN progression. They should commence annual cervical screening from first sexual activity or age 25 (whichever comes first) rather than waiting until the standard programme age.
Women who have never been sexually active
HPV is almost exclusively sexually transmitted. Women who have never been sexually active are extremely unlikely to have acquired HPV and may reasonably discuss with their clinician whether cervical screening is appropriate. However, women who become sexually active at any age should enter the cervical screening programme promptly.
Women post-hysterectomy
Women who have had a total hysterectomy (removal of the cervix) for benign indications and have no previous high-grade CIN history can safely exit cervical screening. Women who had a subtotal hysterectomy (cervix retained) should continue standard cervical screening. Women who had hysterectomy for CIN 3 or cervical cancer require vault surveillance.
Pregnancy and abnormal cervical smear
CIN does not progress rapidly in pregnancy and treatment is not performed during pregnancy due to bleeding risk and risk to the fetus. Diagnostic colposcopy with biopsy of high-grade-appearing lesions is acceptable in pregnancy. Definitive treatment is deferred to 6–12 weeks postpartum. Invasive cancer in pregnancy requires urgent oncology input.
| HPV Test Result | Cytology | Management |
|---|---|---|
| HPV Not Detected | N/A | Routine recall (3yr <50; 5yr 50-64) |
| HPV 16/18 Detected | Any result | Immediate colposcopy referral |
| Other hrHPV Detected | Normal | Repeat HPV test in 12 months |
| Other hrHPV Detected | Borderline / Low-grade | Colposcopy referral |
| Other hrHPV Detected | High-grade (mod/severe) | Urgent colposcopy referral |
| HPV Positive, 12m repeat | HPV still positive | Colposcopy referral |
How does HPV cause cervical cancer?
High-risk HPV types (primarily 16 and 18) integrate their DNA into the host cell genome. The viral oncoproteins E6 and E7 inactivate the tumour suppressor proteins p53 and Rb respectively, disrupting cell cycle control and apoptosis. This leads to accumulation of genetic mutations, progressive dysplasia (CIN), and ultimately invasion through the basement membrane — completing the transition from precancer to invasive squamous cell carcinoma (approximately 15–20 year timeline) or adenocarcinoma.
Does the HPV vaccine prevent cervical cancer?
Yes. The nonavalent HPV vaccine (Gardasil 9) protects against HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, which together cause approximately 90% of cervical cancers. Vaccination before first sexual exposure provides near-complete protection against vaccine-type HPV. Real-world data from Scotland and Sweden show that girls vaccinated before age 14 have approximately 87–90% lower cervical cancer incidence. Vaccination does not eliminate the need for cervical screening.
What is colposcopy?
Colposcopy is a specialist outpatient examination of the cervix using a colposcope (a magnifying instrument) after application of dilute acetic acid and Lugol's iodine. CIN-bearing epithelium turns white with acetic acid (acetowhite change) and fails to take up iodine (iodine-negative). The colposcopist visualises the transformation zone — the area of highest cancer risk — and takes targeted biopsies of abnormal areas for histological diagnosis.
What is the difference between CIN and cervical cancer?
CIN (Cervical Intraepithelial Neoplasia) refers to abnormal cells confined to the surface epithelium of the cervix — it is a precancerous condition. Cervical cancer has invaded through the basement membrane into the underlying stroma (connective tissue). CIN does not spread or cause metastases; cervical cancer can spread to lymph nodes, adjacent organs, and distant sites. The transition from CIN 3 to invasive cancer typically takes many years, providing ample opportunity for intervention.
Can men be tested for HPV?
There is no licensed HPV screening test for asymptomatic men, as the natural history of HPV in men and the benefit of testing are less clear-cut than in women. However, HPV vaccination is offered to boys and men (UK: up to age 25 in GBMSM; US: all adolescents at 11–12 years) to protect against HPV-related conditions in both sexes: genital warts, anal cancer, penile cancer, head and neck oropharyngeal cancer.
How should women be managed after LLETZ for CIN?
UK NHS guidance: HPV testing 6 months after treatment. If HPV negative at 6 months: return to 3-year recall. If HPV positive or incomplete excision: re-biopsy and possible further treatment. Continued elevated risk for 10 years post-treatment means enhanced surveillance in the UK programme. LLETZ excision with clear margins significantly reduces recurrence risk compared to incomplete excision.
Does cervical screening detect glandular lesions (adenocarcinoma)?
Primary HPV testing significantly improves detection of glandular lesions and adenocarcinoma in situ (CGIN) compared to cytology-only screening, as HPV drives adenocarcinoma as well as squamous cell carcinoma. However, glandular lesions are located higher in the endocervical canal and may be missed on both cytology and colposcopy. CGIN requires cone biopsy for complete excision and has a higher recurrence risk than CIN.
When should women stop cervical screening?
UK: women screened up to age 64 who have been consistently negative can exit the programme. US USPSTF: screening can stop at age 65 if adequate prior screening has been documented (3 consecutive normal cytology results or 2 negative co-tests in the past 10 years, with the most recent within 5 years). Women with a history of CIN 2–3 should continue surveillance beyond 65 according to their post-treatment follow-up plan.
Proffstips
Always document whether the transformation zone (TZ) was fully visible at colposcopy — an adequate colposcopy requires the entire squamocolumnar junction (SCJ) to be seen. Inadequate colposcopy (TZ not fully visible) significantly reduces the negative predictive value of a reassuring colposcopy and may warrant cone biopsy for complete TZ assessment.
Visste du?
Dr Harald zur Hausen received the 2008 Nobel Prize in Physiology or Medicine for discovering that human papillomavirus (HPV) causes cervical cancer — a finding he first proposed in the 1970s, long before it was accepted. His work led directly to the development of HPV vaccines, which have the potential to eliminate cervical cancer as a public health problem within this century.